IMUC - ImmunoCellular Therapeutics Issues Shareholder Letter Providing Update on ICT-107 Program in Newly Diagnosed Glioblastoma Highlights Include ICT-107 Results to Date, Ongoing Data Analyses and Phase III Planning
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.